0.2637
0.46%
0.0046
Schlusskurs vom Vortag:
$0.2591
Offen:
$0.269
24-Stunden-Volumen:
403.00K
Relative Volume:
0.38
Marktkapitalisierung:
$4.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.59M
KGV:
-0.0109
EPS:
-24.29
Netto-Cashflow:
$-16.49M
1W Leistung:
+1.82%
1M Leistung:
-2.36%
6M Leistung:
-62.33%
1J Leistung:
-99.03%
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
TransCode Therapeutics Inc (RNAZ) expanding its growth trajectory ahead - SETE News
TransCode reports progress in metastatic breast cancer treatment By Investing.com - Investing.com Australia
Transcode Therapeutics announces publication of study on TTX-MC138 - TipRanks
TransCode reports progress in metastatic breast cancer treatment - Investing.com
TransCode reports progress in metastatic breast cancer treatment By Investing.com - Investing.com Canada
Upward Trajectory: TransCode Therapeutics Inc (RNAZ) Posts a Slidee, Closing at 0.26 - The Dwinnex
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing - The Bakersfield Californian
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer - StockTitan
Do investors need to be concerned about TransCode Therapeutics Inc (RNAZ)? - US Post News
TransCode Therapeutics (NASDAQ:RNAZ) Rating Reiterated by HC Wainwright - Defense World
TransCode shares hold price target as analyst reiterates Buy rating - Investing.com
RNAZTransCode Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Transcode Therapeutics awarded $2M NIH grant to support TTX-MC138 - TipRanks
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate - StockTitan
Examining TransCode Therapeutics Inc (RNAZ) more closely is necessary - US Post News
Nanodrug targeting miR-10b shows promise in treating metastatic breast cancer - MSN
TransCode Therapeutics (NASDAQ:RNAZ) Stock Quotes, Forecast and News Summary - Benzinga
TransCode Therapeutics faces Nasdaq delisting over equity, price By Investing.com - Investing.com Australia
Nanodrug targeting miR-10b shows promise in treating metastatic breast cancer - News-Medical.Net
Nanodrug targeting miR-10b shows promise in treating metastatic breast cancer - Head Topics
miR-10b inhibition: A strategy for treating metastatic breast cancer - Medical Xpress
TransCode Therapeutics faces Nasdaq delisting over equity, price By Investing.com - Investing.com Canada
TransCode Therapeutics faces Nasdaq delisting over equity, price - Investing.com
miR-10b Inhibition: A strategy for treating metastatic breast cancer - EurekAlert
Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock Quotes, Forecast and News Summary - Benzinga
TransCode Therapeutics Inc (RNAZ) can make a big difference with a little luck - SETE News
Analytical Lens: Exploring TransCode Therapeutics Inc (RNAZ)’s Financial Story Through Ratios - The Dwinnex
Associated Banc-Corp (NYSE:ASB) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Transcode Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com Australia
TransCode Therapeutics (NASDAQ:RNAZ) Stock Rating Reaffirmed by HC Wainwright - Defense World
SG Americas Securities LLC Acquires New Holdings in Spirit AeroSystems Holdings, Inc. (NYSE:SPR) - Defense World
Transcode Therapeutics faces Nasdaq delisting over bid price - Investing.com
Transcode Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com South Africa
Transcode Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com UK
TransCode Therapeutics begins Phase I trial of metastatic cancer therapy - Yahoo Finance
RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024 - InvestorPlace
The time has not yet come to remove your chips from the table: TransCode Therapeutics Inc (RNAZ) - SETE News
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation - StockTitan
Transcode Therapeutics stock hits 52-week low at $0.23 By Investing.com - Investing.com Canada
Transcode Therapeutics stock hits 52-week low at $0.23 By Investing.com - Investing.com UK
TransCode Therapeutics Inc: Rising -99.81% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Sees Large Increase in Short Interest - Defense World
Balance Sheet Breakdown: TransCode Therapeutics Inc (RNAZ)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
TransCode Therapeutics Inc (RNAZ) stock on the rise: An overview - US Post News
10,490 Shares in Inventiva S.A. (NASDAQ:IVA) Bought by Virtu Financial LLC - Defense World
Virtu Financial LLC Has $39,000 Stock Holdings in T2 Biosystems, Inc. (NASDAQ:TTOO) - Defense World
Insider’s View: Deciphering TransCode Therapeutics Inc (RNAZ)’s Financial Health Through Ratios - The Dwinnex
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Where Do Analysts Think The TransCode Therapeutics Inc (NASDAQ: RNAZ) Is Going - Stocks Register
The growth track for TransCode Therapeutics Inc (RNAZ) has changed recently - SETE News
TransCode Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):